Scarica l'app Stockscreener
2.37
4.44%
-0.11
Dopo l'orario di chiusura:
2.43
0.06
+2.53%
C 4 Therapeutics Inc Borsa (CCCC) Ultime notizie
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - PharmiWeb.com
C4 Therapeutics Announces Stock and Warrants Offering - TipRanks
Revenues Working Against C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Share Price Following 38% Dive - 富途牛牛
C4 Therapeutics Lines Up $125 Million To Fund Cancer Trials - Finimize
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering - The Globe and Mail
C4 Therapeutics, Inc. Announces $125 Million Underwritten Offering to Advance Cemsidomide Multiple Myeloma Development - Quiver Quantitative
C4 Therapeutics Presents Phase 1 Trial Data - TipRanks
C4 Therapeutics, Inc. Presents Phase 1 Trial Data for Cemsidomide - TradingView
C4 Therapeutics prices equity deal; warrants could lift net to $341.7M - Stock Titan
Is C4 Therapeutics Inc. still worth holding after the dipStop Loss & Weekly High Return Opportunities - newser.com
Live market analysis of C4 Therapeutics Inc.Sell Signal & Daily Oversold Stock Bounce Ideas - newser.com
When is the best time to exit C4 Therapeutics Inc.Recession Risk & AI Based Buy and Sell Signals - newser.com
How C4 Therapeutics Inc. stock reacts to oil pricesJuly 2025 Decliners & Fast Entry Momentum Alerts - newser.com
Real time social sentiment graph for C4 Therapeutics Inc.2025 Valuation Update & Precise Buy Zone Tips - newser.com
C4 Therapeutics Inc. stock trend forecastWeekly Risk Summary & High Yield Equity Trading Tips - newser.com
Will C4 Therapeutics Inc. stock maintain momentum in 20252025 Fundamental Recap & Reliable Price Breakout Alerts - newser.com
Using Ichimoku Cloud for C4 Therapeutics Inc. technicalsJuly 2025 Pullbacks & Real-Time Chart Pattern Alerts - newser.com
ETFs Investing in C4 Therapeutics, Inc. Stocks - TradingView
C4 Therapeutics, Inc.Common Stock (NQ: - FinancialContent
User - FinancialContent
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The AI Journal
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics Reports Promising Phase 1 Trial Results - MSN
C4 Therapeutics (NASDAQ:CCCC) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat
C4 Therapeutics Inc Stock Analysis and ForecastVolume Spike Alerts & Low Risk Trading Ideas - earlytimes.in
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Is C4 Therapeutics Inc. trending in predictive chart modelsWeekly Risk Report & High Yield Equity Trading Tips - newser.com
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Will C4 Therapeutics Inc. bounce back from current supportBreakout Watch & Low Drawdown Momentum Ideas - newser.com
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
What analysts say about C4 Therapeutics Inc stockCup and Handle Formations & Capital Allocation Recommendations - earlytimes.in
Is Onix Solar Energy Limited Undervalued or Overvalued Fair Value ExplainedHigh Frequency Trading Trends & Small Entry Investment Ideas - earlytimes.in
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics Announces Clinical Trial Collaboration and - GlobeNewswire
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Karyopharm
1.84%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):